Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Abstract

Fluvastatin treatment in patients with average cholesterol levels undergoing their first successful PCI significantly reduces the risk of major adverse cardiac events.

Impact of Omega-3 Supplementation on High Sensitive C-Reactive Protein Level and 30-Day Major Adverse Cardiac Events After the Implementation of Coronary Stent in Patients with Chronic Kidney Disease: A Randomized Clinical Study

“… 24 The significant effect of pre-treatment with fluvastatin on reducing MACE was also reported in patients with average cholesterol levels undergoing their first successful PCI. 25 Although non-significant, our study showed similar results like the above studies since both baseline hs-CRP and the difference between baseline and 24-h hs-CRP plus 30-day MACE were higher in control group compared to omega-3 group.…”

Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis

“…Based on these unique properties, in patients with CAD, earlier statin therapy provided better clinical outcomes regardless of LDL cholesterol levels or clinical presentations [7, 20–22]. In the present study, consistent with the findings of previous observational and randomized trials [7, 20–22], we reaffirmed that statin therapy at hospital discharge was associated with improved hard clinical outcomes such as all-cause death or MI after coronary revascularization. Therefore, given that our study has contributed further evidence of the consistent clinical benefits of statins for secondary prevention, further implementation of statin therapy should be required in patients with angina undergoing coronary revascularization.…”

Effects of Statins on Restenosis After Coronary Stent Implantation

“…In addition, the LIPS study showed that statin treatment in patients with normal cholesterol levels undergoing their first successful percutaneous coronary intervention reduced the risk of major adverse cardiac events. 5 This evidence may greatly support the results of our study.…”